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Nonsteroidal-anti-inflammatory-drug (NSAID) enteropathy is characterized by small intestinal damage and ulceration. Emu Oil
(EO) has previously been reported to reduce intestinal inflammation.Aim.We investigated EO for its potential to attenuate NSAID-
enteropathy in rats.Methods. Male Sprague Dawley rats (𝑛 = 10/group) were gavaged with Water, Olive Oil (OO), or EO (0.5mL;
days 0–12) and with 0.5mL Water or the NSAID, Indomethacin (8mg/kg; days 5–12) daily. Disease activity index (DAI), 13C-
sucrose breath test (SBT), organ weights, intestinal damage severity (IDS), and myeloperoxidase (MPO) activity were assessed.
𝑃 < 0.05was considered significant.Results. In Indomethacin-treated rats, DAI was elevated (days 10–12) and SBT values (56%) and
thymusweight (55%)were decreased, relative to normal controls. Indomethacin increased duodenum (68%), colon (24%), SI (48%),
caecum (48%), liver (51%) and spleen (88%)weights, IDS scores, andMPO levels (jejunum: 195%, ileum: 104%) compared to normal
controls. Jejunal MPO levels were decreased (64%) by both EO and OO, although only EO decreased ileal MPO (50%), compared
to Indomethacin controls. Conclusions. EO reduced acute intestinal inflammation, whereas other parameters of Indomethacin-
induced intestinal injury were not affected significantly. Increased EO dose and/or frequency of administration could potentially
improve clinical efficacy.
1. Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) are among
the most widely prescribed pharmaceutical agents, with
approximately 30 million patients worldwide ingesting
NSAIDs daily [1, 2]. NSAIDs have been indicated as an
effective treatment option for rheumatic andmusculoskeletal
conditions [3] and to potentially lower the risk of cardio-
vascular and cerebrovascular insults. Indeed, recent studies
have indicated efficacy for the treatment of colon cancer
[2, 4]. NSAIDs represent a highly effective class of drug;
however, their use is often associated with a broad spectrum
of adverse effects, predominantly within the gastrointesti-
nal (GI) tract [2, 3]. The adverse events in the stomach,
duodenum, jejunum, and ileum are collectively termed
NSAID-gastroenteropathy [5].
NSAID-associated intestinal toxicity has several manifes-
tations including increased mucosal permeability, inflamma-
tion and ulceration, and in severe cases, bowel perforation
[5]. Clinically evident features include anaemia, bleeding,
mucosal diaphragms, strictures, and chronic bowel inflam-
mation [6]. Serious injury to the small intestine (SI) has been
estimated to account for one-third of all NSAID-associated
complications [6].
The pathogenesis of NSAID-enteropathy is proposed
to commence via a direct intestinal insult together with
its enterohepatic and consequent systemic effects [3, 5, 7].
Entrance of the acidic NSAID into enterocytes induces
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severe stress in the endoplasmic reticulum and mitochon-
dria leading to cell death [3, 8]. An increase in mucosal
permeability follows, which facilitates the translocation and
action of luminal factors such as bile acids, dietary macro-
molecules, components of pancreatic juice, and bacteria,
thereby activating the inflammatory cascade [8, 9]. Within
the mucosa, tumor necrosis factor-𝛼 (TNF-𝛼) expression
promotes autoregulation and expression of other proinflam-
matory cytokines including interleukin-1𝛽 (IL-1𝛽) and IL-6
[10]. Furthermore, neutrophils are recruited and infiltrated at
the area of ulceration [3, 5, 10].
Commonly prescribed NSAIDs include Aspirin, Ibupro-
fen, Naproxen, Ketoprofen, and Indomethacin [4]. The
enzyme, cyclooxygenase (COX), which exists as two iso-
forms, is the target for NSAID action. COX converts arachi-












), and thromboxane (TXA
2
) [11]. The
two isoforms of COX generally have distinct functions;
COX-1-derived PGs maintain mucosal integrity whereas
COX-2 is rapidly induced in response to proinflamma-
tory stimuli leading to PG production at inflammatory
sites [12].
Historically, GI injury has been primarily associated
with nonselective COX-1/2 inhibitors. On the basis of these
findings, selective COX-2 inhibitors including Celecoxib and
Meloxicam were developed. These were initially reported
to elicit analgesic properties accompanied by minimal GI
inflammatory side effects [13]. However, a number of recent
reports have suggested that the incidence of jejunal and ileal
injury induced by chronic use of selective COX-2 inhibitors
may be as high as nonselective therapies [5, 14–16]. The
development of new therapies is therefore imperative to
ameliorate the side effects of NSAID use, particularly in
patients undergoing long-term NSAID-treatment.
Favorable effects of diets high in n-3 polyunsaturated fatty
acids (PUFAs) have been well documented in inflammatory
conditions including rheumatoid arthritis [17] and inflamma-
tory bowel disease (IBD) [18]. Cell culture studies with n-
3 PUFAs have shown inhibition of COX-2 production and
proinflammatory cytokines including TNF-𝛼, interleukin-1
(IL-1), IL-6, IL-8, and IL-12 [19–21]. Furthermore, animal
studies with marine oils rich in n-3 PUFAs support the in
vitro observations. For example, Fish Oil reduced levels of
TNF-𝛼, IL-12, and IL-1𝛽 in a mouse model of IBD [22].
Recently, attention has been directed towards animal-derived
oils with high levels of PUFAs, such as the oil derived from the
Australian ratite bird, the Emu (Dromaius novaehollandiae)
[23, 24].
Indigenous Australians first used Emu Oil to facilitate
wound healing, pain alleviation and treatment of inflamed
joints [23, 25, 26]. Topical application of Emu Oil decreased
levels of TNF-𝛼 and IL-1𝛼 in a mouse model of adjuvant-
induced inflammation [27]. These cytokines are involved in
the pathogenesis of NSAID-enteropathy [5]. Abimosleh et al.
[24] reported that orally administered Emu Oil improved
selected parameters associated with the manifestation of
experimental IBD in rats. Furthermore, Lindsay et al. [28]
demonstrated that Emu Oil reduced ileal myeloperoxidase
activity indicative of neutrophil infiltration and improved
mucosal architecture in a rat model of intestinal mucositis.
Therefore, we hypothesized that orally administered Emu
Oil would protect against Indomethacin-induced enteropa-
thy in rats.
2. Materials and Methods
2.1. General Experimental Procedures
2.1.1. Animal Studies. Throughout acclimatization and the
experimental period, male Sprague Dawley rats (140–170 g)
were individually housed in metabolism cages (Tecniplast,
PA, USA) at room temperature with a light:dark cycle of
12 hours. All rats were given ad libitum access to food
(standard 18% casein-based diet [29]) and water, and were
acclimatized for 2 days prior to experimentation. All animal
studies were conducted in compliance with the Australian
Code of Practice for the Care and Use of Animals and were
approved by the Animal Ethics Committees of the Children,
Youth and Women’s Health Service and The University of
Adelaide.
Rats were randomly assigned to four groups (𝑛 =
10/group): Group 1: Water + Water, Group 2: Indometha-
cinm+Water, Group 3: Indomethacin +OliveOil, andGroup
4: Indomethacin + Emu Oil. Water, Olive Oil, or Emu Oil
(0.5mL) was administered once daily (morning) via oro-
gastric gavage from days 0 to 12. Between days 5 and 12, rats
were administered Water (0.5mL) or Indomethacin (Sigma-
Aldrich, MO, USA; 8mg/kg) via oro-gastric gavage (4 hours
after morning gavage).
The dose of Indomethacin (8mg/kg) was determined
from a pilot study using male Sprague Dawley rats, which
was performed immediately prior to the current study.
Indomethacin dosages (6mg/kg, 8mg/kg, and 10mg/kg)
were tested and 8mg/kg was deemed to be the most appro-
priate for the current investigation, based upon metabolic
parameters, disease activity index (DAI), and kill data.
2.1.2. Emu Oil and Olive Oil Preparation. Commercially
available Emu Oil, sourced from Emus farmed in North-
Eastern South Australia, was prepared utilizing specific
methodologies developed for Technology Investment Corpo-
ration by Emu Tracks (Marleston, Adelaide, South Australia).
Briefly, these processes involved the rendering and filtration
of Emu adipose tissue, with appropriate considerations for
delivery of quality assurance and product consistency. Fatty
acid analysis of Emu Oil and Olive Oil was carried out using
gas chromatography, as described previously [30] (Table 1).
Commercially available Olive Oil (Conga Foods, Spain) was
selected as the control oil due to its high level of oleic
acid; similar to that of Emu Oil. The Olive Oil control was
included to determine any nonspecific oil-related effects for
subsequent comparison with Emu Oil. Both Emu Oil and
Olive Oil were individually stored at 4∘C in 50mL opaque
containers.
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Table 1: Major fatty acid (FA) composition of Emu and Olive Oils
used in the current study including unsaturated fatty acid (UFA)
and saturated fatty acid (SFA) ratios. Monounsaturated fatty acid
(MUFA); polyunsaturated fatty acid (PUFA).
Major FA composition of Emu and Olive Oils
Fatty acid Common name Emu Olive
16 : 0 Palmitic acid 24 10.4
16 : 1n-7 Palmitoleic acid 4.3 0.7
18 : 0 Stearic acid 8.5 3.1
18 : 1n-9 Oleic acid 49.1 73.9
18 : 2n-6 Linoleic acid 9.5 8.4




UFA: SFA ratio 2 6.2
2.2. Daily Metabolic Data and Disease Activity Index. Body
weight, food and water intake, and fecal and urine output
were monitored and measured daily. The severity of NSAID-
induced enteropathy was assessed in a blinded fashion daily,
using a DAI, which scored body weight loss, rectal bleeding,
stool consistency, and overall general condition of the animal,
increasing in severity on a scale of 0–3 for each parameter,
which was totaled to achieve an overall DAI, as described
previously [31, 32]. Overall condition was determined by
(1) mobility/agility: healthy rats are considered quite active,
whereas rats affected by Indomethacin characteristically
become very weak and feeble, sitting hunched with very little
movement and (2) fur: healthy rats are well-groomed with
fur flat to the body, whereas rats administered Indomethacin
become scruffy in appearance, with ruffled fur.
2.3. 13C-Sucrose Breath Test. Immediately prior to kill (day
12), the 13C-sucrose breath test (SBT) was performed as a
noninvasive assessment of the functional status of SI health
and to ensure safety of Emu Oil [33]. Briefly, following an
overnight fast, a baseline breath sample was collected at 𝑡 =
0. Rats were then gavaged with 1mL of a 25% 13C-labeled
sucrose solution (BDH, Merck Pty Ltd., Victoria, Australia);
breath samples were collected every 15 minutes for 120
minutes, and samples were analyzed for 13CO
2
concentration
using an isotope ratio mass spectrometer (Europa Scientific,
Crewe, UK) [34]. Data were expressed as mean percentage
cumulative dose of 13C recovered at 90 minutes after sucrose
administration (%CD90). This provides an indirect indica-
tion of the rate at which sucrose is cleaved by the enzyme
sucrase in the SI, and therefore, the level of sucrase present
on SI enterocytes (brush border).
2.4. Tissue Collection. On day 12, rats were sacrificed by CO
2
asphyxiation followed by cervical dislocation. The GI tract
was removed, measured, emptied of contents, and weighed.
Furthermore, the SI tract (jejunum, jejunum-ileum junction
[JI], and the ileum)was opened for intestinal damage severity
assessment. Segments of the SI tract (4 cm) were collected at
approximately 10% (jejunum) and 90% (ileum) of the total
SI length and snap-frozen in liquid nitrogen for biochemical
analysis. Samples were stored at −80∘C until prepared for
analysis by homogenization in 10mM phosphate buffer.
The remaining visceral organs (thymus, lungs, heart, liver,
kidneys, and spleen) were weighed and discarded.
2.5. Intestinal Damage Severity Scoring. Intestinal damage
severity (IDS) was assessed utilizing a quantitative scoring
system based on thirteen parameters. Opened intestinal sec-
tions (jejunum, JI and ileum) were inspected and quantified
for erythema (small: <2 cm, large: ≥2 cm; Figure 1(b)), mild
hemorrhage (small: <2 cm, large: ≥2 cm; Figure 1(b)), severe
hemorrhage (small: <2 cm, large: ≥2 cm; Figure 1(c)), single
ulcers (small: <0.5 cm, medium: ∼0.5 cm, large: >0.5 cm;
Figure 1(d)), cluster of ulcers (small:<4, large:≥5; Figure 1(e))
and perforations (small: <0.5 cm, large: ≥0.5 cm; Figure 1(f)),
in which number, size, and location were recorded on a
schematic intestinal diagram during kill. Assessment was
performed in a blinded fashion using a dissectingmicroscope
(Leica Microsystems, Wetzlar, Germany). Raw parameter
datawere totaled to achieve an overall score for each intestinal
section from each rat.
2.6. Biochemical Analysis
2.6.1.Myeloperoxidase Activity. Myeloperoxidase (MPO) lev-
els in the SI were determined as an indicator of neutrophil
infiltration, and hence, acute inflammation, using techniques
described by Howarth et al. [35].Thawed, homogenised sam-
ples were centrifuged at 13,000 g for 12 minutes, after which
the supernatant was discarded, and the tissue homogenate
was resuspended in 200𝜇L of 0.5% hexadecyltrimethyl
ammonium bromide buffer, a detergent (Sigma Chemicals,
Sydney, Australia). After vortexing for 2 minutes, samples
were again centrifuged at 13,000 g for 2minutes. Background,
negative and positive control samples (50𝜇L) and the super-
natants of each test sample were then aliquoted into duplicate
wells of a microtiter 96-well plate. Following the addition
of a reaction solution (200𝜇L to each well; 4.2mg of O-





potassiumphosphate buffer [pH 6.0], 22.5mL distilledwater)
the change in absorbancewasmeasured at 450 nm at 1minute
intervals for 15 minutes with a spectrophotometer (Victor
X4 Multilabel Reader, Perkin Elmer, Singapore). Data were
expressed as units of MPO per gram of tissue.
2.7. Statistical Analyses. Statistical comparisons were con-
ducted using SPSS version 16.0 for Windows (SPSS Inc.,
Chicago, Illinois,USA).All data setswere tested for normality
of distribution using the Shapiro-Wilk statistic. Metabolic
data were analysed using a one-way ANOVA and Tukey’s post
hoc test to compare groups during each period, prior to (days
0–4) and during (days 5–12) Indomethacin administration.
SBT, visceral and gastrointestinal organ weights and lengths,
intestinal damage severity, and MPO activity were analysed
using a one-way ANOVA with Tukey’s post hoc test. All




Figure 1: Macroscopic aspects of opened rat small intestinal sections representing (a) no damage, (b) erythema and hemorrhage, (c) severe
hemorrhage, (d) large single ulcer, (e) large cluster of ulcers, and (f) perforations. These parameters were utilized in the intestinal damage
severity scoring system.
parametric data were expressed as mean with their standard
errors. DAI comparisons between groups each dayweremade
using a Kruskal Wallis test with Mann-Whitney U tests and
expressed as median (range). For all analyses, 𝑃 < 0.05 was
considered significant.
3. Results
3.1. Daily Metabolic Data. During the period prior to com-
mencement of Indomethacin administration (days 0–4),
OliveOil and EmuOil did not significantly affect bodyweight
gain, total food and water intake, and total urine output
(𝑃 > 0.05; Table 2) compared to normal, healthy controls.
However, Olive Oil significantly reduced total fecal output in
normal rats, compared to normal controls (25%; days 0–4;
𝑃 < 0.05).
Body weight was determined as a mean percent-
age change from the commencement of Indomethacin
or water administration (days 5–11). Water-gavaged rats
gained approximately 25% body weight from day 5 to 11,
whereas Indomethacin administration resulted in signifi-
cantly reduced weight gain in normal rats compared to
normal controls (𝑃 < 0.001; Table 3). Neither of the oil
treatments increased body weight in Indomethacin-treated
rats compared to Indomethacin-treated controls (𝑃 > 0.05;
Table 3).
Table 2: Body weight (% change from starting body weight), total
food (g) and water (mL) intake and total fecal (g) and urine (mL)
output in normal rats during the period prior to Indomethacin
administration (days 0–4). Ratswere gavaged dailywithWater,Olive
Oil, or Emu Oil (0.5mL).
Water Olive Oil Emu Oil
Body weight (%) 14.8 ± 0.5 14.8 ± 0.6 14.4 ± 0.6
Food intake (g) 85.1 ± 1.5 83.4 ± 1.9 84.6 ± 2
Water intake (mL) 353.6 ± 38.9 429.4 ± 50.6 425.6 ± 58.6
Fecal ouput (g) 7.8 ± 0.4 6.1 ± 0.5∗ 7.1 ± 0.3
Urine ouput (mL) 65.2 ± 3.6 66.9 ± 6.5 68.2 ± 4.2
∗
𝑃 < 0.05 compared to Water group.
Data are expressed as mean (%, g or mL) ± standard error of the mean.
Indomethacin significantly decreased total food intake
(41%) and increased water intake (72%) in normal rats
compared to healthy controls during days 5–12 (𝑃 < 0.001;
Table 3). Olive Oil and Emu Oil did not significantly affect
total food or water intake in Indomethacin-treated rats com-
pared to Indomethacin controls (𝑃 > 0.05). Indomethacin
significantly decreased (21%; 𝑃 < 0.01) total fecal output
during days 5–12 compared to healthy controls, which was
subsequently normalized following Olive Oil and Emu Oil
treatment (𝑃 < 0.05; Table 3). Neither Indomethacin nor the
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Table 3: Body weight (% change from starting body weight), total food (g) and water (mL) intake and total fecal (g) and urine (mL) output
in rats during Indomethacin administration (days 5–12). Rats were gavaged daily with Water, Olive Oil, or Emu Oil (0.5mL) throughout the
experimental period and commenced daily gavage with water or Indomethacin (Indo; 8mg/kg) on day 5. Rats were fasted overnight on day
11 and therefore day 12 body weight data was not included.
Water + Water Indo + Water Indo + Olive Oil Indo + Emu Oil
Body weight (%) 23.1 ± 0.8 1.6 ± 3.3∗∗∗ 6.0 ± 2.4 4.6 ± 2.0
Food intake (g) 132.8 ± 1.6 78.2 ± 4.9∗∗∗ 83.9 ± 4.3 77.9 ± 4.4
Water intake (mL) 416 ± 51.3 715.1 ± 72.1∗∗ 651.7 ± 53.1 655.9 ± 66.1
Fecal ouput (g) 12.8 ± 0.4 10.1 ± 0.6∗∗ 12.4 ± 0.5∧ 12.4 ± 0.7∧
Urine ouput (mL) 104.2 ± 8.5 87.8 ± 3.1 85.4 ± 6.2 98.8 ± 7.3
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Figure 2: Overall functional status of small intestinal health in rats
assessed utilizing the 13C sucrose breath test on day 12. Rats were
gavaged daily withWater, OliveOil, or EmuOil (0.5mL) throughout
the experimental period and commenced daily gavage with water or
Indomethacin (8mg/kg) on day 5. Data are expressed as mean (%
cumulative dose of 13C at 90 minutes; %CD90) ± standard error of
the mean. ∗∗∗ indicates 𝑃 < 0.001 compared to Water + Water.
oil treatments significantly affected total urine output (𝑃 >
0.05; Table 3).
3.2. Disease Activity Index (DAI). Indomethacin significantly
increased DAI in normal rats on day 10 (median score 1
(range: 0–7); 𝑃 < 0.01), 11 (2 (1–7); 𝑃 < 0.001) and 12 (2 (1–8);
𝑃 < 0.001) compared to healthy controls (0 (0); Table 4). Oil
treatments did not significantly affect DAI in Indomethacin-
treated rats compared to Indomethacin controls (𝑃 > 0.05).
3.3. 13C-Sucrose Breath Test (SBT). Indomethacin signif-
icantly decreased percentage cumulative dose of 13C at
90 minutes (%CD90) compared to healthy controls (56%
decrease; 𝑃 < 0.001; Figure 2). However, both oil treatments
failed to significantly increase %CD90 in Indomethacin-
administered animals compared to Indomethacin controls
(𝑃 > 0.05; Figure 2).
3.4. Visceral and Gastrointestinal Organ Weights and Lengths.
Organweightswere expressed as a proportion of bodyweight.
Significant increases in duodenum (68%; 𝑃 < 0.05), SI (48%;
𝑃 < 0.001), caecum (48%; 𝑃 < 0.001), and colon (24%;
𝑃 < 0.05) weights were evident in normal rats administered
Indomethacin compared to healthy controls (Table 5). Oil
treatments did not significantly affect duodenum, SI, cae-
cum, or colon weights in Indomethacin-treated rats (𝑃 >
0.05) compared to Indomethacin controls. There were no
significant differences in visceral organ weights including
heart, lungs, left kidney, right kidney, and stomach following
Indomethacin or oil treatments (𝑃 > 0.05; Table 5).
Indomethacin significantly increased (51%) liver weight
in normal rats compared to healthy controls (𝑃 < 0.001;
Table 5). Thymus weight in Indomethacin-treated rats was
decreased (55%) compared to healthy controls (𝑃 < 0.001;
Table 5). Indomethacin significantly increased spleen weight
in normal rats compared to healthy controls (88%; 𝑃 <
0.001; Table 5). Neither Olive Oil nor Emu Oil treatment
significantly affected liver, thymus, or spleen weights in
rats administered Indomethacin compared to Indomethacin
controls (𝑃 > 0.05; Table 5).
Neither Indomethacin nor oil treatments significantly
affected duodenum or colon length (𝑃 > 0.05; Table 6). SI
length in rats administered Indomethacin was significantly
decreased compared to normal controls (41%; 𝑃 < 0.001;
Table 6); however, neither Emu Oil nor Olive Oil affected SI
length compared to Indomethacin controls.
3.5. Intestinal Damage Severity (IDS) Scoring. IDS scores in
the jejunum, JI, and ileum were significantly greater in rats
administered Indomethacin, compared to normal controls
(𝑃 < 0.001; Figure 3). Neither of the oil treatments decreased
the overall IDS in rats administered Indomethacin, compared
to Indomethacin controls (𝑃 > 0.05; Figure 3).
3.6. Myeloperoxidase (MPO) Activity. Jejunal MPO activity,
indicative of acute inflammation, was increased by 195%
following Indomethacin administration, compared to healthy
controls (𝑃 < 0.01; Figure 4(a)). In the jejunum, both
Olive Oil and Emu Oil significantly decreased MPO activity
in Indomethacin-treated rats compared to Indomethacin
controls (64%; 𝑃 < 0.01). Ileal MPO activity was signif-
icantly elevated in normal rats administered Indomethacin
compared to healthy controls (104%; 𝑃 < 0.01; Figure 4(b)).
However, in the ileum, only Emu Oil significantly reduced
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Table 4: Disease activity index (DAI) of rats gavaged daily with 0.5mL of Water, Olive Oil, or Emu Oil throughout the experimental period
(days 0–12) and administered water or Indomethacin (Indo; 8mg/kg) daily on day 5. Data are expressed as median disease activity index
score (range).
Day of trial Water + Water Indo + Water Indo + Olive Oil Indo + Emu Oil
6 0 (0) 0 (0) 0 (0) 0 (0)
7 0 (0) 0 (0) 0 (0) 0 (0)
8 0 (0) 0 (0–2) 0 (0) 0 (0)
9 0 (0) 0 (0–6) 0 (0-1) 0 (0–3)
10 0 (0) 1 (0–7)∗∗ 1 (0–3) 0 (0–4)
11 0 (0) 2 (1–7)∗∗∗ 2 (0–4) 1 (0–5)
12 0 (0) 2 (1–8)∗∗∗ 3 (0–5) 2 (0–7)
∗∗∗
𝑃 < 0.001, ∗∗𝑃 < 0.01 compared to Water + Water.
Table 5: Organ weight following adjustment for rat body weight. Rats were gavaged daily with 0.5mL of Water, Olive Oil, or Emu Oil
throughout the experimental period (days 0–12) and administered water or Indomethacin (Indo; 8mg/kg) daily from day 5.
Weight (%) Water + Water Indo + Water Indo + Olive Oil Indo + Emu Oil
Thymus 27 ± 1 12 ± 3∗∗∗ 13 ± 2 14 ± 2
Heart 42 ± 0 41 ± 2 42 ± 2 40 ± 1
Lungs 62 ± 3 59 ± 4 61 ± 4 57 ± 3
L Kidney 40 ± 1 43 ± 1 41 ± 1 41 ± 2
R Kidney 44 ± 4 42 ± 1 52 ± 6 42 ± 2
Liver 352 ± 9 533 ± 23∗∗∗ 525 ± 25 537 ± 29
Spleen 30 ± 1 56 ± 5∗∗∗ 58 ± 3 64 ± 5
Stomach 56 ± 2 66 ± 7 59 ± 11 57 ± 4
Duodenum 22 ± 1 37 ± 5∗ 49 ± 5 39 ± 6
SI 178 ± 5 263 ± 38∗∗∗ 330 ± 17 270 ± 40
Caecum 29 ± 1 43 ± 2∗∗∗ 46 ± 3 46 ± 3
Colon 38 ± 1 47 ± 1∗ 50 ± 2 49 ± 3
Data are expressed as mean (% relative to body weight) ± standard error of the mean.
All values ×10−2. ∗∗∗𝑃 < 0.001, ∗𝑃 < 0.05 compared to Water + Water.
MPO activity in Indomethacin-administered rats compared
to Indomethacin controls (50%; 𝑃 < 0.05; Figure 4(b)). Olive
Oil did not significantly affect ileal MPO activity (𝑃 > 0.05).
4. Discussion
NSAIDs have beenwidely used to achieve analgesic, antinoci-
ceptive, and anti-inflammatory effects; however, amajor limi-
tation ofNSAIDusage has been related toGI side effects. Emu
Oil has been reported to reduce the severity of experimentally
induced inflammatory GI disorders including IBD [24] and
chemotherapy-induced intestinal mucositis [28].The current
study indicated that Emu Oil reduced SI neutrophil infil-
tration and normalized total fecal output in a rat model of
Indomethacin-induced enteropathy. Furthermore, Emu Oil
treatment significantly increased liver and spleen weight and
decreased thymus weight relative to Indomethacin controls.
However, Emu Oil treatment failed to improve most other
parameters associated with Indomethacin-induced SI dam-
age.
In the current study, an 8mg/kg Indomethacin dose was
employed, resulting in clinicalmanifestationswhich included
significantly decreased food intake accompanied by weight
loss and reduced fecal output and increased water intake,
with no changes in urine output. Furthermore, elevated DAI,
reduced brush border sucrase activity, as assessed indirectly
by the SBT and elevated IDS were observed. In a study
by Kamil et al. [2], rats were administered Indomethacin
daily at 6mg/kg for 7 days to induce enteropathy. Interest-
ingly, no clinical signs of enteropathy were observed, high-
lighting the clinical significance of minor dosage increases
of Indomethacin. Clinical manifestations of Indomethacin-
enteropathy were not improved by Olive Oil or Emu Oil
treatment. Moreover, fecal output was increased following oil
treatment relative to Indomethacin controls, consistent with
the study by Abimosleh et al. [24] in a rat model of IBD.
This may have represented a normalization of fecal output
compared to Indomethacin controls. Alternatively, increased
water intake coincident with the absence of changes in urine
outputmay have indicatedwater loss in stools and subsequent
dehydration.
In the current study, Indomethacin decreased SI length,
a phenomenon reported to be a compensatory mechanism
in response to intestinal damage to increase mucosal sur-
face area [36] and potentially protect the intestine from
pathogenic invasion. Furthermore, Indomethacin increased
duodenum, SI, and colonic weight. Although not quanti-
fied, these weight increases may have represented mucosal,
Evidence-Based Complementary and Alternative Medicine 7
Table 6: Gastrointestinal organ length of rats gavaged daily with 0.5mL of Water, Olive Oil, or Emu Oil throughout the experimental period
(days 0–12) and administered water or Indomethacin (Indo; 8mg/kg) daily from day 5.
Length (cm) Water + Water Indo + Water Indo + Olive Oil Indo + Emu Oil
Duodenum 6.5 ± 0.3 5.6 ± 0.3 6.6 ± 0.4 6.2 ± 0.4
SI 78.5 ± 2.2 46.2 ± 2.1∗∗∗ 51.0 ± 3.4 51.0 ± 3.4
Colon 12.9 ± 0.4 11.8 ± 0.6 12.0 ± 0.4 12.2 ± 0.5
Data are expressed as mean (cm) ± standard error of the mean.
∗∗∗
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Figure 3: Intestinal damage severity score in the rat jejunum,
jejunum-ileum junction (JI), and ileumon day 12. Rats were gavaged
daily with 0.5mL of Water, Olive Oil, or Emu Oil throughout
the experimental period (days 0–12) and administered water or
Indomethacin (Indo; 8mg/kg) daily from day 5. Data are expressed
as mean (severity score) ± standard error of the mean. ∗∗∗ indicates
𝑃 < 0.001 compared to Water + Water.
submucosal or muscularis hyperemia and oedema, poten-
tially combined with inflammatory cell infiltration and the
associated exudate. This would likely cause an increase in GI
weight. Emu Oil did not improve Indomethacin-enteropathy
manifestations associated with intestinal weights.
Recent studies have hypothesized that neutrophil activa-
tion is an important primary event preceding Indomethacin-
induced SI injury [37]. Fukumoto et al. [10] demonstrated
that tissue-associated neutrophil accumulation, assessed
by MPO activity, and keratinocyte chemoattractant (KC)
mRNA expression, involved in chemotaxis and neutrophil
activation, were significantly increased in Indomethacin-
treated SI mucosa [10]. Furthermore, MPO levels and KC
mRNA expression were reduced in TNF-𝛼-deficient mice
treated with Indomethacin compared to wild-type. This
indicated a protective role of TNF-𝛼 deficiency in decreas-
ing Indomethacin-induced SI mucosal injury [10]. In the
current study, Indomethacin increased MPO activity in the
jejunum and ileum. Both Olive Oil and Emu Oil treatment
significantly decreasedMPO activity, indicative of neutrophil
infiltration, in the Indomethacin-damaged jejunum. Impor-
tantly, only Emu Oil decreased MPO levels in the ileum,
relative to Indomethacin controls. Emu Oil has previously
been shown to reduce levels of TNF-𝛼 in a croton-oil induced
model of auricular swelling [27]. Therefore, the observed
decrease in MPO levels following Emu Oil administration
in the current study may have been the result of suppressed
TNF-𝛼 expression.
PUFAs influence cytokine production, lymphocyte pro-
liferation, and macrophage activation state through mod-
ulation of AA (common n-6 PUFA) metabolism [38]. n-3
PUFAs replace AA from phospholipid membranes, thereby
reducing the availability of AA to COX and thus reduc-
ing the production of PGs involved in the inflammatory
cascade such as the 2-series eicosanoids. Furthermore, n-3
PUFAs can be directly metabolized by COX, resulting in the
production of anti-inflammatory 3-series eicosanoids [38].
Cell culture studies with n-3 PUFAs eicosapentanoic acid
(EPA) and docosahexaenoic acid (DHA) have been shown
to inhibit lipopolysaccharide-induced production of COX-2,
and proinflammatory cytokines including TNF-𝛼, IL-1, IL-
6, IL-8, and IL-12 in endothelial cells [19, 20]. Furthermore,
animal feeding studies with Fish Oil, a source of EPA and
DHA, supported in vitro observations of decreased cytokine
production [22, 39, 40]. Further studies of Emu Oil could
benefit from a complete time-course of cytokine profiling
to identify potential effects on proinflammatory cytokine
antagonism.
Liver weight was significantly increased in the current
study following Indomethacin (8mg/kg), compared to
normal controls. In a previous rat model of Indomethacin-
enteropathy, daily administration of Indomethacin at
6mg/kg did not result in significant liver weight changes.
The impact of Indomethacin on liver weight therefore
appears to be dose-dependent as Ilic et al. [41], consistent
with the current findings, demonstrated liver weight
increases in male albino Wistar rats injected daily for
three days with 12.5mg/kg of diclofenac (NSAID). The
authors observed pronounced parenchymal necrosis,
elevated eosinophilic hepatocytes, extensive microvesicular
steatosis, and sinusoidal dilation [41]. Moreover, TNF-𝛼,
directly linked to the pathogenesis of enteropathy, binds
to TNF-RI cell death receptors leading to hepatocyte
apoptosis followed by accumulation of neutrophils [42].
Future studies would benefit from liver enzyme analyses
including gamma-glutamyl transpeptidase (GGT), alanine
aminotransaminase (ALT), alkaline phosphotase (ALP),
and bilirubin, which elevate in NSAID-induced toxicity
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Figure 4:Myeloperoxidase activity indicative of acute inflammation
in the rat (a) jejunum and (b) ileum on day 12. Data are expressed
as mean (myeloperoxidase activity; units per gram; U/g) ± standard
error of the mean. Rats were gavaged daily with 0.5mL of Water,
Olive Oil or Emu Oil throughout the experimental period (days
0–12) and administered water or Indomethacin (Indo; 8mg/kg)
daily from day 5. ∗∗ indicates 𝑃 < 0.01 compared to Water +
Water; ∧∧ indicates 𝑃 < 0.01, ∧ indicates 𝑃 < 0.05 compared to
Indomethacin + Water.
[43]. Furthermore, histological assessment of Kupffer cells,
resident liver macrophages [44], hepatotoxic lymphocytes
including CD4+, CD8+ T cells and natural killer cells and
apoptotic hepatocytes [45] would provide greater insight
into the hepatic impact of Indomethacin.
In the current study, Olive Oil and Emu Oil treatment
to rats which were administered Indomethacin did not
significantly affect liver weight, relative to Indomethacin
controls. Abimosleh et al. [24] examined liver weight in
healthy Sprague Dawley rats, which was not significantly
affected by Olive Oil or Emu Oil. This indicated that
the current findings were directly related to Indomethacin
administration with no effect of oil administration. Valen-
zuela et al. [46] demonstrated that n-3 long-chain PUFA
supplementation induced an antioxidant response preventing
liver steatosis in mice fed a high fat diet. This was further
supported by a study in which Fish Oil in combination with
Indomethacin decreased the severity of liver steatosis in a
mouse model of familial hypercholesterolemia [38]. Based
upon the n-3 PUFAs present in Emu Oil and its reported
antioxidant activity [47], liver steatosis seems less likely in
the current study. However, a high n-6/n-3 PUFA ratio has
been implicated in nonalcoholic FA liver disease [48] and
therefore it would be beneficial to determine the effects
of FA ratio and n-9 FA levels on liver function in future
studies.
Thymus weight was significantly decreased following
administration of 8mg/kg Indomethacin in the current study,
relative to normal controls. Kamil et al. [2] did not report any
thymus weight changes using 6mg/kg of oral Indomethacin.
However, a single subcutaneous injection of Indomethacin at
35mg/kg significantly decreased thymus weight in rats after
three days in a study by Filaretova et al. [36], consistent with
the current study. Furthermore, the increased spleen weight
evident following Indomethacin administration in the cur-
rent study should be pursued in relation to the thymus weight
decreases. Such studies could determine the contribution
of T (CD4+ and CD8+) and B lymphocyte upregulation or
suppression in the thymus and spleen, respectively. However,
neither Olive Oil nor Emu Oil significantly affected thymus
or spleen weight.
5. Conclusions
In summary, when administered once daily to rats, Emu Oil
significantly reduced acute inflammatory activity associated
with Indomethacin-induced enteropathy. However, although
encouraging, it appears likely that increased dose and/or
frequency of administration will need to be explored in order
to achieve demonstrable clinical benefit in the setting of
NSAID-enteropathy.
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